FDA Clearance Tracker · K171974
Solana RSV+hMPV Assay
Last checked: Nov 20, 2026Latest source record: Oct 16, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Oct 16, 2017
Substantially Equivalent
Time to decision
108 days
Received Jun 30, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K171974
- Device name
- Solana RSV+hMPV Assay
- Applicant
- Quidel Corporation
- Applicant location
- Athens, OH
- Received
- Jun 30, 2017
- Decided
- Oct 16, 2017
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3980
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OCC. The earliest in FDA's data is DEN070013, decided Jan 3, 2008.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K171974
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Quidel Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- QuickVue COVID-19 Test510(k)
K231795 · Decided Mar 22, 2024 · 276 days after receipt
Device type: Over-The-Counter Covid-19 Antigen Test (QYT) · Laboratory Medicine & Pathology
K232286 · Decided Dec 20, 2023 · 141 days after receipt
Device type: Herpes Virus (Vzv, Hsv1, Hsv2), Dna Detection Assay For Cutaneous And Mucocutaneous Lesion Samples (PGI) · Laboratory Medicine & Pathology
K233688 · Decided Dec 13, 2023 · 26 days after receipt
Device type: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings (QVF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.